- Home
- ATAI
as 06-20-2025 4:00pm EST
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
| Founded: | 2018 | Country: | Germany |
| Employees: | N/A | City: | BERLIN |
| Market Cap: | 444.7M | IPO Year: | 2021 |
| Target Price: | $10.50 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $2.64 | Next Earning Date: | 08-12-2025 |
| Revenue: | $1,863,000 | Revenue Growth: | 572.56% |
| Revenue Growth (this year): | 554.22% | Revenue Growth (next year): | -81.02% |
Stock Insider Trading Activity of ATAI Life Sciences N.V. (ATAI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Apeiron Investment Group Ltd. | ATAI | 10% Owner | Mar 24 '25 | Buy | $1.40 | 1,800,000 | $2,520,000.00 | 42,369,415 |
Latest ATAI Life Sciences N.V. News
ATAI Breaking Stock News: Dive into ATAI Ticker-Specific Updates for Smart Investing
TipRanks
3 days ago
Trump Trade: President said to weigh possible U.S. strike against Iran
TipRanks
3 days ago
Psychedelic advocates hopeful Trump administration will support space, STAT says
WSJ
3 days ago
This Illegal Psychedelic Is Hailed as a ‘Revolutionary Breakthrough’
GlobeNewswire
20 days ago
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
GlobeNewswire
24 days ago
atai Life Sciences to Participate in Upcoming Investor Conferences
TipRanks
a month ago
Phase 2a data for BPL-003 ‘encouraging’ for Atai Life Sciences, says Jefferies
TipRanks
a month ago
Home Depot backs outlook as U.S. sales ticked up: Morning Buzz
GlobeNewswire
a month ago
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
Compare ATAI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATAI ATAI Life Sciences N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.